Context. SAGE-718 (Sage Therapeutics) is an oral N -methyl-d-aspartate receptor (NMDAR) Positive Allosteric Modulator (PAM) being developed for cognitive impairment in Huntington’s disease. Aberrant NMDAR signaling has been implicated in several neurological and psychiatric disorders, making the receptor an attractive drug target. Although [...]
5 minute read
Aug. 26, 2022
SAGE-718: an Oral N-methyl-d-Aspartate Receptor (NMDAR) Positive Allosteric Modulator
SAGE-718
oral NMDAR positive allosteric modulator Ph. II candidate in neurology from previously disclosed PAM and opt J. Med. Chem., July 2, 2022 Sage Therapeutics, Inc., Cambridge, MA